WO2011114338A1 - A process for the preparation of highly pure ambrisentan - Google Patents
A process for the preparation of highly pure ambrisentan Download PDFInfo
- Publication number
- WO2011114338A1 WO2011114338A1 PCT/IN2010/000153 IN2010000153W WO2011114338A1 WO 2011114338 A1 WO2011114338 A1 WO 2011114338A1 IN 2010000153 W IN2010000153 W IN 2010000153W WO 2011114338 A1 WO2011114338 A1 WO 2011114338A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ambrisentan
- reaction mass
- solution
- preparation
- ethyl acetate
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Definitions
- the present invention relates to an improved and novel process for the preparation of highly pure (>99.8%) (+)-2(S)-(4,6-Dimethylpyrimidin-2-yloxy)-3-methoxy-3,3- diphenylpropionic acid (Ambrisentan) of formula-I
- Ambrisentan which is (+)-2(S)-(4,6-Dimemylpyrimidin-2-yloxy)-3-methoxy-3,3- diphenylprOpionic acid having the formula - 1 is approved under the trademark "Letairis” by the US Food and Drug Administration for the treatment of Pulmonary artery hypertension(P AH) .
- methyl 2-hydroxy-3-methoxy-3,3-diphenylpropionate (II) is dissolved in DMF and sodium hydride is added. The mixture is stirred for a hour and then 4,6- dimethyl-2-(methylsulfonyl)pyrimidine is added. After stirring at room temperature for 24hours cautious hydrolysis is carried out with water , the pH is adjusted to 5 with acetic acid. , and the solvent is removed under high vacuum. The residue is taken up in ethyl acetate, washed with water and the solvent is distilled out. The residue is mixed with ether and the resulting precipitate is filtered off.
- step-2 the step-1 product is hydrolyzed in IN KOH solution in dioxane medium at reflux temperature. After reaction completion the reaction mass is washed with ethyl acetate to remove unreacted ester. The pH of the aqueous layer is adjusted with coned. HCl pH 1-2 and extracted with ethyl acetate. After water washing, ethyl acetate is distilled off and the product was liberated by the addition of ether/hexane mixture.
- the above process adds two more steps to the Route of synthesis viz., esterification and hydrolysis
- DMF is added dropwise to a suspension of sodium hydride in DMF. The mixture is stirred for an hour and then 4,6-dimemyl-2-memylsulfonylpyrirnidine in DMF is added.
- mole ratio of S- 2-hydroxy-3-methoxy-3,3-diphenylpropionic acid , 4,6- dime&yl-2-memylsulfonylpyrimidine and sodium hydride is 1:1.3:3.0 .
- the objective of this invention is to prepare highly pure Ambrisentan through acid addition salts (l:l)of Ambrisentan.
- Ambrisentan of higher purity results.
- the main object of the present invention is to provide an improved process for the preparation of highly pure (>99.8%) Ambrisentan
- Another object of the invention is to provide a process for preparation of salts of Ambrisentan with S(-)4-nitro phenyl ethyl amine or S(-)-phenyl ethyl amine in high purity(>99.8%).
- Ambrisentan is prepared by .
- Treating Ambrisentan with S(-)4-nitro phenyl ethylamine or S(-)-phenyl ethyl amine yielding the corresponding addition salt of Ambrisentan iii.
- the present invention provides the following process for the ⁇ preparation of Ambrisentan
- the reaction mass is maintained at 25-30°C for 16-17hours
- aqueous layer pH is adjusted with IN hydrochloride solution to 2-3 during 30-45 minutes
- reaction mass is maintained under stirring for 2hours at RT
- reaction mass temperature is raised to reflux
- reaction mass is maintained at reflux temperature for 1 hours
- reaction mass is brought to room temperature and maintained at the same
- Ambrisentan S-(-)4-nitro phenyl ethyl amine /S(-)-phenyl ethyl amine acid addition salts(l .l) are novel and are identified and characterized by chemical analysis, IR, NMR & Mass spectral. Ambrisentan acid addition salts are further converted to Ambrisentan as follows : i. Ambrisentan S-(-)4-nitro phenyl ethyl amine or S(-)-phenyl ethyl amine addition salt is acidified with diluted hydrochloric acid
- reaction mass is maintained at room temperature for 2-3hours
- Example- 1 Process for the preparation highly pure Ambrisentan of the formula -I
- Step-1 Condensation of S(+) 2-hydroxy-3-methoxy-3,3-diphenylpropionic acid 4,6-dimethyl-2-(-(methylsulfonyl)pyrimidine in DMF medium
- DMF(400ml) and S-2-Hydroxy-3-mehoxy- 3,3-diphenyl propionic acid(50g) were, charged and stirred for 30 minutes.
- sodium hydride(18.9g) was added slowly for lhour and reaction mass was maintained at room temperature for one hours.
- Step - II Preparation of Ambrisentan S(-)4-nitro phenyl ethylamine addition salt(l:l) : Ambrisentan (60g, purity 99.5%) was dissolved in acetone (900ml) and S-(-)4-nitro phenyl ethyl amine(26.2g) was added to the solution over 30 min . Reaction mass ' ⁇ temperature was raised to reflux and maintained for about l-2hrs. Reaction mass was slowly cooled to room temperature and maintained for about 16-18 hr at the same temperature. The precipitated material was filtered and washed with 200mlof acetone.
- the product was dried at 60-70°C under vacuum till constant weight.
- Step - III Preparation of highly pure Ambrisentan from Ambrisentan S(-)P-nitro phenyl ethylamine addition salt (1:1):
- Ambrisentan .S(-)4-nitro phenyl ethyl amine addition salt(60g) was suspended in DM W water(3L)and stirred for 15minutes.
- Aqueous IN hydrochloric acid solution(500) was added over a period of 30 min to a pH of 1-2 and maintained at the same temperature for 2-3hours.
- the precipitated product was filtered and washed with purified water. The product was dried at temperature of 60-70°C till constant weight.
- Example-2 Process for the preparation highly pure Ambrisentan of the formula -I
- Step-1 Condensation of S(+) 2-hydroxy-3-methoxy-3,3-diphenylpropionic acid and 4,6-dimethyl-2-(-(methylsulfonyl)pyrimidine in THF medium
- Reaction mass was quenched into DM water (15L) and acidified with diluted hydrochloric acid(600ml). Reaction mass was maintained under stirring for 3hours at room temperature. Filtered compound was dissolved in Ethyl acetate and ethyl acetate layer was extracted with IN sodium hydroxide solution(2L) Sodium hydroxide layer was separated and acidified with IN hydrochloride solution(l .25L) . Reaction mass was maintained under stirring for 2hours . The product of the formula-I was filtered and washed with purified water. It was dried in oven at 60-65 °C
- Step - II Preparation of Ambrisentan S(-) phenyl ethylamine addition salt(l:l) : Ambrisentan (50g, purity 99.5%) was dissolved in acetone (500ml) and S-(-) phenyl ethyl amine(16.0g) was dissolved in acetone(32ml)added to the solution over 30 min . Reaction mass temperature was raised to reflux and maintained for about l-2hrs. Reaction mass was slowly cooled to room temperature and maintained for about 16-18 hr at the same temperature. The precipitated material was filtered and washed with 200mlof acetone. The product was dried at 60-70°C under vacuum till constant weight. Dry weight : 40g
- Step - III Preparation of highly pure Ambrisentan from Ambrisentan S(-) phenyl ethylamine addition salt(l :l) :
- Ambrisentan .S(-) phenyl ethyl amine addition salt(40g) was suspended in DM water(2L)and stirred for 15minutes.
- Aqueous IN hydrochloric acid solution(330ml) was added over a period of 30 min to a pH of 1-2 and maintained at the same temperature for 2-3hours.
- the precipitated product was filtered and washed with purified water. The product was dried at temperature of
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020127026731A KR20130054250A (en) | 2010-03-15 | 2010-03-15 | A process for the preparation of highly pure ambrisentan |
US13/635,299 US20130060031A1 (en) | 2010-03-15 | 2010-03-15 | Process for the preparation of highly pure ambrisentan |
PCT/IN2010/000153 WO2011114338A1 (en) | 2010-03-15 | 2010-03-15 | A process for the preparation of highly pure ambrisentan |
EP10725507A EP2547663A1 (en) | 2010-03-15 | 2010-03-15 | A process for the preparation of highly pure ambrisentan |
CA2792473A CA2792473A1 (en) | 2010-03-15 | 2010-03-15 | A process for the preparation of highly pure ambrisentan |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/IN2010/000153 WO2011114338A1 (en) | 2010-03-15 | 2010-03-15 | A process for the preparation of highly pure ambrisentan |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2011114338A1 true WO2011114338A1 (en) | 2011-09-22 |
Family
ID=42813438
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IN2010/000153 WO2011114338A1 (en) | 2010-03-15 | 2010-03-15 | A process for the preparation of highly pure ambrisentan |
Country Status (5)
Country | Link |
---|---|
US (1) | US20130060031A1 (en) |
EP (1) | EP2547663A1 (en) |
KR (1) | KR20130054250A (en) |
CA (1) | CA2792473A1 (en) |
WO (1) | WO2011114338A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103524424A (en) * | 2012-07-04 | 2014-01-22 | 天津药物研究院 | Crystal form VI of ambrisentan as well as preparation method and application thereof |
CN103524425A (en) * | 2012-07-04 | 2014-01-22 | 天津药物研究院 | Crystal form V of ambrisentan as well as preparation method and application thereof |
WO2014139086A1 (en) * | 2013-03-12 | 2014-09-18 | 江苏康缘药业股份有限公司 | Method for preparing ambrisentan |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996011914A1 (en) | 1994-10-14 | 1996-04-25 | Basf Aktiengesellschaft | New carboxylic acid derivatives, their preparation and their use |
WO2001005771A1 (en) | 1999-07-20 | 2001-01-25 | Basf Aktiengesellschaft | Novel carboxylic acid derivatives with 5,6 substituted pyrimidine ring, the production and utilization thereof as endothelin receptor antagonists |
-
2010
- 2010-03-15 CA CA2792473A patent/CA2792473A1/en not_active Abandoned
- 2010-03-15 KR KR1020127026731A patent/KR20130054250A/en not_active Application Discontinuation
- 2010-03-15 WO PCT/IN2010/000153 patent/WO2011114338A1/en active Application Filing
- 2010-03-15 US US13/635,299 patent/US20130060031A1/en not_active Abandoned
- 2010-03-15 EP EP10725507A patent/EP2547663A1/en not_active Withdrawn
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996011914A1 (en) | 1994-10-14 | 1996-04-25 | Basf Aktiengesellschaft | New carboxylic acid derivatives, their preparation and their use |
US5932730A (en) | 1994-10-14 | 1999-08-03 | Basf Aktiengesellschaft | Carboxylic acid derivatives, their preparation and use |
WO2001005771A1 (en) | 1999-07-20 | 2001-01-25 | Basf Aktiengesellschaft | Novel carboxylic acid derivatives with 5,6 substituted pyrimidine ring, the production and utilization thereof as endothelin receptor antagonists |
Non-Patent Citations (3)
Title |
---|
DATABASE JOURNAL OF MEDICINAL CHEM [Online] 1 May 1996 (1996-05-01), RIECHERS H ET AL: "DISCOVERY AND OPTIMIZATION OF A NOVEL CLASS OF ORALLY ACTIVE NONPEPTIDIC ENDOTHELIN-A RECEPTOR ANTAGONISTS", XP002023887, retrieved from CHEMICAL PAN - 91407 * |
J. MED. CHEM., vol. 39, no. 11, 1996, pages 2123 - 2128 |
J. MED. CHEM., vol. 39, no. LL, 1996, pages 2123 - 2128 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103524424A (en) * | 2012-07-04 | 2014-01-22 | 天津药物研究院 | Crystal form VI of ambrisentan as well as preparation method and application thereof |
CN103524425A (en) * | 2012-07-04 | 2014-01-22 | 天津药物研究院 | Crystal form V of ambrisentan as well as preparation method and application thereof |
WO2014139086A1 (en) * | 2013-03-12 | 2014-09-18 | 江苏康缘药业股份有限公司 | Method for preparing ambrisentan |
Also Published As
Publication number | Publication date |
---|---|
KR20130054250A (en) | 2013-05-24 |
CA2792473A1 (en) | 2011-09-22 |
EP2547663A1 (en) | 2013-01-23 |
US20130060031A1 (en) | 2013-03-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8962832B2 (en) | Process for the preparation of ambrisentan and novel intermediates thereof | |
WO2013026391A1 (en) | Synthesis method of azoxystrobin and exclusive intermediate in the synthesis thereof | |
EP2602250B1 (en) | Method for preparing rosuvastatin calcium intermediate | |
CA2848631A1 (en) | Rilpivirine hydrochloride | |
KR20170029506A (en) | Process for the preparation of 4-alkoxy-3-hydroxypicolinic acids | |
US7227021B2 (en) | Process for preparing 1-methoxymethyl-5,5-diphenylbarbituric acid | |
US20090099362A1 (en) | Process for the preparation of gabapentin hydrochloride | |
EP2547663A1 (en) | A process for the preparation of highly pure ambrisentan | |
US20130184490A1 (en) | Process to prepare s-2-hydroxy-3-methoxy-3,3-diphenyl propionic acid | |
US6187926B1 (en) | Process for producing quinolone derivatives | |
CN109988070B (en) | Intermediate of trans-1-hydroxy-1- (trifluoromethyl) -3-aminocyclobutane hydrochloride, preparation method and application | |
CA3136883A1 (en) | Process for the preparation of fungicidally active strobilurin compounds and intermediates thereof | |
EP3356372B1 (en) | Novel process for preparing thienopyrimidine compound and intermediates used therein | |
CN114685375A (en) | Preparation method of [2- (6-chloropyrimidine-4-oxygen) phenyl ] -3, 3-dimethoxyacrylic acid methyl ester | |
US9212120B2 (en) | Process for preparing spiro[2.5]octane-5,7-dione | |
US20140275535A1 (en) | Acid addition salts of bosentan | |
CN104447527A (en) | Method for preparing pyridine-2,3-dicarboxylic ester compound | |
US7223882B2 (en) | Process for producing triterpene derivative | |
JP4356111B2 (en) | Process for producing N- (2-amino-1,2-dicyanovinyl) formamidine | |
US20130245259A1 (en) | Process for the preparation of bosentan monohydrate | |
JP2003500333A (en) | Method for producing 4-[(2 ', 5'-diamino-6'-halogenpyrimidin-4'-yl) amino] cyclopent-2-enylmethanol | |
JP2000327629A (en) | Phenylacetic acid derivative, benzonitrile derivative and production thereof | |
WO2023100110A1 (en) | Process for preparing brivaracetam | |
WO2011121598A1 (en) | Crystalline 7-[4-(4-fluorophenyl)-6-isopropyl-2-(methanesulfonyl-methyl-amino)-pyrimidin-5-yl]-3(r)-hydroxy-5-oxo-hept-6-enoic acid methyl ester and process thereof | |
JP2000327652A (en) | Phthalonitrile derivative and its production |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10725507 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2792473 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010725507 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 20127026731 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13635299 Country of ref document: US |